利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

76 条记录 (耗时 0.034 秒)

    Methods of treating diseases with anti-VEGF antibodies
    34.
    发明授权
    Methods of treating diseases with anti-VEGF antibodies 失效
    用抗VEGF抗体治疗疾病的方法

    公开(公告)号：US07482005B2

    公开(公告)日：2009-01-27

    申请号：US11682197

    申请日：2007-03-05

    申请人： Kyung Jin Kim

    发明人： Kyung Jin Kim

    IPC分类号： A61K39/395 ,  C07K16/22

    CPC分类号： C07K16/22 ,  A61K38/00 ,  A61K47/6425 ,  A61K47/6811 ,  A61K47/6843 ,  A61K2039/505 ,  C07K14/52 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

    摘要： The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.

    摘要翻译： 本发明提供能够特异性结合人血管内皮细胞生长因子（hVEGF）或hVEGF相关蛋白的单克隆抗体及其部分。 本发明还提供了产生这种单克隆抗体的杂交瘤细胞系。 本发明的单克隆抗体本身或与细胞毒性或其它化学治疗剂联用可用作治疗剂，以治疗以过量血管内皮细胞增殖为特征的疾病。 本发明的单克隆抗体也可用于测定样品中hVEGF或hVEGF相关蛋白的存在的诊断和分析方法。

    Antibodies to vascular endothelial cell growth factor
    35.
    发明授权
    Antibodies to vascular endothelial cell growth factor 失效
    血管内皮细胞生长因子的抗体

    公开(公告)号：US07227004B2

    公开(公告)日：2007-06-05

    申请号：US10441728

    申请日：2003-05-20

    申请人： Kyung Jin Kim

    发明人： Kyung Jin Kim

    IPC分类号： C07K16/22 ,  C12N5/12

    CPC分类号： C07K16/22 ,  A61K38/00 ,  A61K47/6425 ,  A61K47/6811 ,  A61K47/6843 ,  A61K2039/505 ,  C07K14/52 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

    摘要： The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.

    摘要翻译： 本发明提供能够特异性结合人血管内皮细胞生长因子（hVEGF）或hVEGF相关蛋白的单克隆抗体及其部分。 本发明还提供了产生这种单克隆抗体的杂交瘤细胞系。 本发明的单克隆抗体本身或与细胞毒性或其它化学治疗剂联用可用作治疗剂，以治疗以过量血管内皮细胞增殖为特征的疾病。 本发明的单克隆抗体也可用于测定样品中hVEGF或hVEGF相关蛋白的存在的诊断和分析方法。

    Antibodies to leukemia inhibitory factor and their use in immunoassays
    36.
    发明授权
    Antibodies to leukemia inhibitory factor and their use in immunoassays 失效
    白血病抑制因子的抗体及其在免疫测定中的应用

    公开(公告)号：US06544749B1

    公开(公告)日：2003-04-08

    申请号：US09321935

    申请日：1999-05-28

    申请人： Kyung Jin Kim

    发明人： Kyung Jin Kim

    IPC分类号： G01N3353

    CPC分类号： C07K16/244 ,  A61K38/00 ,  C07K2317/74

    摘要： The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.

    摘要翻译： 本发明涉及人白血病抑制因子的单克隆抗体。 所公开的单克隆抗体被认为在hLIF上识别出独特的表位，并且可用于治疗其中hLIF的存在引起或有助于不期望的病理学作用，例如恶病质，调节钙代谢或过度骨细胞增殖的病症，并且在 检测hLIF，例如临床样本或标本。